BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17350920)

  • 1. [Treatment of hepatitis C in patients on renal replacement therapy].
    Tornai I; Mátyus J
    Orv Hetil; 2007 Mar; 148(11):489-94. PubMed ID: 17350920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hepatitis C infections in dialyzed patients].
    Podlasin RB
    Przegl Epidemiol; 2005; 59(2):541-7. PubMed ID: 16190565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure].
    Vallet-Pichard A; Pol S
    Nephrol Ther; 2015 Nov; 11(6):507-20. PubMed ID: 26423779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of HCV infected patients and renal disease.
    Kershenobich D
    Ann Hepatol; 2010; 9 Suppl():103-6. PubMed ID: 20714005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation.
    Manz M; Steuerwald M
    Transpl Infect Dis; 2007 Mar; 9(1):60-1. PubMed ID: 17313476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
    Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study.
    Fabrizi F; D'Ambrosio R; Pallotti F; Berardinelli L; Messa P; Martin P; Aghemo A
    Int J Artif Organs; 2014 Nov; 37(11):803-8. PubMed ID: 25362901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of hepatitis C: from empiricism to eradication.
    Pawlotsky JM
    Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
    Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
    Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.
    Biselli M; Andreone P; Gramenzi A; Lorenzini S; Loggi E; Bonvicini F; Cursaro C; Bernardi M
    Dig Liver Dis; 2006 Jan; 38(1):27-32. PubMed ID: 16311084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report.
    Nakano R; Ohira M; Ishiyama K; Ide K; Kobayashi T; Tahara H; Shimizu S; Arihiro K; Imamura M; Chayama K; Tanaka Y; Ohdan H
    Transplant Proc; 2017 Sep; 49(7):1634-1638. PubMed ID: 28838454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.
    Bizollon T; Ducerf C; Trépo C
    J Hepatol; 1995; 23 Suppl 2():22-5. PubMed ID: 8720290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?
    Merli M; Gentili F; Giusto M; Attili AF; Corradini SG; Mennini G; Rossi M; Corsi A; Bianco P
    Dig Liver Dis; 2009 May; 41(5):345-9. PubMed ID: 19162574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
    N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatitis C virus infection in patients with end-stage renal disease.
    Liu CH; Kao JH
    J Gastroenterol Hepatol; 2011 Feb; 26(2):228-39. PubMed ID: 21261711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.
    Chalasani N; Manzarbeitia C; Ferenci P; Vogel W; Fontana RJ; Voigt M; Riely C; Martin P; Teperman L; Jiao J; Lopez-Talavera JC;
    Hepatology; 2005 Feb; 41(2):289-98. PubMed ID: 15660392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.